Last update Oct. 23, 2024

Pentamidine Isetionate

Compatible

Safe product and/or breastfeeding is the best option.

Pentamidine, an aromatic derivative of diamidine, is an antiprotozoal used in the treatment of African trypanosomiasis, some forms of leishmaniasis, in the treatment and prophylaxis of Pneumocystis pneumonia and in other protozoan infections. Given its almost null absorption by oral route, administration is intramuscular or intravenous.

The few pharmacokinetic data known do not allow predicting its possible excretion in breast milk. Its moderately high molecular weight would make this difficult.

Its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period where there may be greater intestinal permeability.

Authorized for use in pediatrics, even in young infants, when there is no alternative treatment. (Pfizer 2022 Sanofi 2021)

List of essential medicines WHO: compatible with breastfeeding. (WHO-UNICEF 2002)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Pentamidine Isetionate in other languages or writings:

Group

Pentamidine Isetionate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Pentamidine Isetionate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. mínima %
Molecular weight 593 daltons
Protein Binding 69 %
T½ 9 - 13 hours

References

  1. Pfizer. Pentamidine. Drug Summary. 2022 Full text (link to original source)
  2. Sanofi-Aventis. Pentamidina. Ficha técnica. 2021 Full text (link to original source)
  3. Kip AE, Schellens JHM, Beijnen JH, Dorlo TPC. Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs. Clin Pharmacokinet. 2018 Abstract Full text (link to original source) Full text (in our servers)
  4. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)

Total visits

4,490

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM